Philip Tsai Buys 12,300 Shares of Immunome, Inc. (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) CTO Philip Tsai bought 12,300 shares of the company’s stock in a transaction dated Monday, March 24th. The stock was purchased at an average cost of $8.42 per share, for a total transaction of $103,566.00. Following the completion of the transaction, the chief technology officer now owns 33,300 shares of the company’s stock, valued at $280,386. This represents a 58.57 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Immunome Price Performance

Shares of IMNM stock traded down $1.20 on Tuesday, hitting $6.95. The company’s stock had a trading volume of 1,747,431 shares, compared to its average volume of 827,029. The stock has a market capitalization of $604.31 million, a price-to-earnings ratio of -0.86 and a beta of 1.93. Immunome, Inc. has a fifty-two week low of $8.12 and a fifty-two week high of $26.70. The firm’s fifty day moving average price is $9.72 and its 200-day moving average price is $11.49.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.16). Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. The firm had revenue of $2.74 million for the quarter, compared to the consensus estimate of $3.07 million. Analysts predict that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on IMNM. Wedbush reiterated an “outperform” rating and set a $33.00 price objective on shares of Immunome in a research report on Thursday, March 20th. Stephens reiterated an “overweight” rating and set a $30.00 price target on shares of Immunome in a report on Thursday, March 20th. Guggenheim lowered their target price on Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a research note on Thursday, March 20th. Finally, Lifesci Capital assumed coverage on shares of Immunome in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price target on the stock. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $25.50.

Hedge Funds Weigh In On Immunome

Several large investors have recently made changes to their positions in the business. BNP Paribas Financial Markets bought a new position in Immunome in the 4th quarter worth approximately $70,000. KLP Kapitalforvaltning AS bought a new position in Immunome during the fourth quarter worth $75,000. AlphaQuest LLC raised its stake in Immunome by 786,700.0% during the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock valued at $84,000 after purchasing an additional 7,867 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in Immunome by 482.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock valued at $91,000 after purchasing an additional 7,129 shares during the period. Finally, Aquatic Capital Management LLC bought a new stake in Immunome in the 4th quarter valued at $95,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.